CA
NZ
UK
AU
IND
US
…
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Estrella Immunopharma Inc. (NASDAQ: ESLA) is limited; the company presents itself as a biotechnology firm focused on immunopharmaceutical development. Longer-term growth may depend on clinical development and regulatory progress of its therapeutic candidates and broader demand for immunotherapies, and investors may find potential upside linked to clinical milestones and technology validation.
Material risks include significant clinical and regulatory uncertainty, probable need for substantial additional capital with attendant dilution, and strong competition in immunotherapy that could limit commercial prospects.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
| Income before tax | -13.06M | -8.85M | -7.31M | - | -0.92M |
| Net income | -13.06M | -8.85M | -7.31M | - | -1.00M |
| Selling general administrative | 2.81M | 1.42M | 3.20M | - | 0.44M |
| Ebit | - | -8.81M | -7.31M | -11.11M | -0.92M |
| Ebitda | -13.06M | -8.85M | - | - | -0.69M |
| Depreciation and amortization | - | -0.04M | - | - | 0.23M |
| Operating income | -13.06M | -8.85M | -7.31M | - | -1.57M |
| Other operating expenses | 13.06M | 8.85M | - | - | 1.57M |
| Tax provision | 0.00M | - | 0.00M | - | 0.00M |
| Income tax expense | 0.00M | 0.00M | - | - | 0.08M |
| Total revenue | 0.00M | - | 0.00M | - | 0.00M |
| Total operating expenses | 13.06M | 8.85M | 7.31M | - | 1.57M |
| Total other income expense net | - | - | - | - | 0.65M |
| Net income from continuing ops | -13.06M | - | -7.31M | - | -6.88M |
| Net income applicable to common shares | - | - | - | -11.11M | -11.11M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
| Total assets | 3.18M | 3.14M | 4.45M | - | 9.99M |
| Other current assets | 0.29M | 0.72M | - | - | 0.01M |
| Total liab | 13.54M | 3.00M | 0.18M | - | 2.92M |
| Total stockholder equity | -10.37M | 0.14M | 4.27M | - | 7.07M |
| Deferred long term liab | - | - | - | 0.28M | 0.28M |
| Other current liab | 12.99M | 3.00M | - | 1.28M | 9.16M |
| Common stock | 0.00M | 0.00M | - | 0.00M | 9.33M |
| Capital stock | 0.00M | - | 0.00M | - | 5.00M |
| Retained earnings | -36.99M | -23.93M | -19.50M | -12.19M | -2.26M |
| Other liab | - | - | - | 0.01M | 0.01M |
| Other assets | - | - | - | 0.28M | 0.28M |
| Cash | 1.38M | 0.92M | 4.17M | - | 0.04M |
| Total current liabilities | 13.54M | 3.00M | 0.18M | 9.76M | 1.07M |
| Net debt | -1.38M | -0.92M | - | - | 0.46M |
| Short term debt | - | - | - | - | 0.50M |
| Short long term debt total | - | - | - | - | 0.50M |
| Other stockholder equity | 26.62M | 24.07M | - | - | 19.26M |
| Total current assets | 1.68M | 1.64M | 4.45M | 2.75M | 0.05M |
| Net tangible assets | - | - | - | -11.74M | -11.74M |
| Net receivables | - | 0.29M | - | 0.27M | 0.27M |
| Accounts payable | 0.55M | - | 0.00M | - | 0.05M |
| Non currrent assets other | 1.50M | 1.50M | - | - | - |
| Non current assets total | 1.50M | 1.50M | 0.00M | - | 9.93M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
| Investments | - | - | 4.96M | - | -0.27M |
| Change to liabilities | - | - | - | 8.39M | 8.39M |
| Total cashflows from investing activities | - | 4.96M | - | -0.27M | 36.17M |
| Net borrowings | - | - | 0.00M | - | 0.00M |
| Total cash from financing activities | 2.25M | -0.49M | 12.79M | - | -35.56M |
| Change to operating activities | - | - | - | 0.98M | 0.98M |
| Net income | -13.06M | -8.85M | -7.31M | -11.11M | -1.00M |
| Change in cash | 0.47M | -8.13M | 1.69M | -1.61M | -0.44M |
| Begin period cash flow | 0.92M | 9.05M | 2.48M | 4.09M | 0.48M |
| End period cash flow | 1.38M | 0.92M | 4.17M | - | 0.04M |
| Total cash from operating activities | -1.79M | -7.64M | -16.07M | -1.34M | -1.04M |
| Issuance of capital stock | 2.40M | - | 9.02M | - | 0.00M |
| Other cashflows from investing activities | - | 4.96M | - | -0.27M | -0.27M |
| Sale purchase of stock | -0.03M | -0.57M | -0.35M | - | -36.11M |
| Other cashflows from financing activities | -0.12M | 9.58M | - | - | 0.05M |
| Change to netincome | - | - | - | 0.41M | 0.41M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 10.62M | 0.78M | -9.95M | - | 0.58M |
| Stock based compensation | 0.62M | 1.19M | 1.19M | - | 0.30M |
| Other non cash items | 0.66M | 0.51M | - | - | -0.65M |
| Free cash flow | -1.79M | -7.64M | -16.07M | - | -1.04M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ESLA Estrella Immunopharma Inc. |
-0.07 6.72% |
0.92 | - | - | - | 4.13 | -3.07 |
| NVO Novo Nordisk A/S |
0.08 0.20% |
39.13 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.44 1.23% |
517.49 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
2.65 0.33% |
807.67 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
| Name | Title | Year Born |
|---|---|---|
| Dr. Cheng Liu Ph.D. | CEO, President & Director | 1967 |
| Jiandong Xu | Chief Financial Officer | NA |
| Dr. Cheng Liu Ph.D. | CEO, President & Director | 1968 |
| Mr. Jiandong Xu | Chief Financial Officer | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.43%
Communication Services
-0.70%
Consumer Cyclical
-0.35%
Consumer Defensive
-0.54%
Energy
+0.40%
Financial Services
-0.54%
Financials
+0.30%
Healthcare
+0.19%
Industrials
+0.38%
Real Estate
+0.22%
Technology
+0.27%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...